AD04 for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Nov 2023: Trial started, NCT07107074
  2. 6 Aug 2025: Trial registered, NCT07107074

The trials

NCT07107074: Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE

State
Under way
Phase
Phase 2
People
122 planned
Started
8 Nov 2023
Primary completion
Dec 2026
Arms
1ml AD04
Results
None posted
  1. 8 Nov 2023: Trial started
  2. 6 Aug 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.